BriaCell (BCTX) Therapeutics announces that the first patient was dosed in its Phase 1/2 study to evaluate the safety and efficacy of Bria-OTS, BriaCell’s personalized next generation immunotherapy. The study will investigate Bria-OTS alone and in combination with immune check point inhibitor tislelizumab for the treatment of metastatic breast cancer. Bria-OTS is an enhanced form of Bria-IMT, currently in pivotal Phase 3 study for metastatic breast cancer. The Phase 1/2 clinical trial will initially evaluate the safety and efficacy of Bria-OTS as monotherapy and, later, in combination with tislelizumab in advanced breast cancer. Key inclusion criteria include metastatic or locally recurrent breast cancer and at least two failed prior attempts of systemic therapy. The study design will include a dose escalation monotherapy phase followed by an expansion phase that will include combination therapy with tislelizumab. Additionally, BriaCell plans to evaluate Bria-OTS+, a more advanced version of the immunotherapy platform, in prostate and other cancers.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BCTX:
- BriaCell Shows Promise in Cancer Immunotherapy Advances
- BriaCell reports preclinical data of personalized off-the-shelf immunotherapies
- BriaCell Unveils Promising Cancer Therapy Data
- BriaCell Therapeutics Faces Uncertain Financial Future
- BriaCell Therapeutics Confronts Financial Challenges Amid Volatile Markets and Potential Shareholder Dilution
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
